Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142307 | 1.00 | FASN (1.00) | FASN | |
| SCHEMBL13276745 | 0.95 | FASN (1.00) | FASN | |
| SCHEMBL29981426 | 0.95 | FASN (1.00) | FASN | |
| SCHEMBL12489445 | 0.95 | FASN (1.00) | FASN | |
| SCHEMBL12489446 | 0.95 | FASN (1.00) | FASN | |
| SCHEMBL13455027 | 0.92 | FASN (0.86) | FASN | |
| SCHEMBL13455292 | 0.92 | FASN (1.00) | FASN | |
| SCHEMBL23367755 | 0.91 | FASN (0.84) | FASN | |
| SCHEMBL12489354 | 0.91 | FASN (1.00) | FASN | |
| SCHEMBL12488813 | 0.91 | FASN (1.00) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023086483-A1 | METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE | SAGIMET BIOSCIENCES INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110177551-B | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-20140322355-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2683244-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885 |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | FASN, FADS1, FADS2 | FASN 1/4885 |
| US-20140322355-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885 |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885 |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | FASN 1/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | FASN 1/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | FASN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.